News

Allulose Patents Granted to Bonumose for Unique Enzymatic Conversion Process

Bonumose is pleased to announce that the U.S. Patent & Trademark Office has issued U.S. Patent No. 11,078,506 for “Enzymatic Production of D-Allulose”.

This patent issuance follows Bonumose’s Allulose U.S. Patent No. 11,053,528 (July 6, 2021) and allulose U.S. Patent No. 10,704,069 (July 7, 2020). Bonumose has been issued additional Allulose patents and/or has patent applications pending in all major sugar-consuming and sugar-producing countries. Bonumose also has a broad patent portfolio for Tagatose production, as well as for related materials and processes.

The global Allulose market recently was described as a “dumpster fire” (Food Navigator-USA, June 28, 2021).

Bonumose’s approach is markedly different from other Allulose producers.

The standard way to produce Allulose involves a low-yield enzymatic conversion of fructose to Allulose – a conversion that is inherently limited because the enzymatic reaction is reversible. There are multiple processing steps, including the following major ones: (1) starch dextrinization; (2) liquefaction to produce glucose; (3) isomerization of glucose to produce a syrup with 42% fructose content (limited yield due to a reversible enzymatic reaction); (4) separation of fructose from glucose and other sugars in the syrup; (5) partial enzymatic conversion of fructose to produce a syrup with 25%-30% Allulose (limited yield due to a reversible enzymatic reaction); (6) separation of Allulose from fructose; and (7) purification and crystallization.

Alternatively, fructose can be produced by (1) hydrolyzing sucrose (sugar), (2) separating the fructose from glucose (theoretical 50% yield), then continuing from step #5 shown above and/or converting the glucose to fructose as in step #3 above.

Bonumose’s patented process is much more streamlined and eliminates several processing steps. After starch dextrinization, Bonumose’s proprietary blend of enzymes combine in an irreversible enzymatic reaction to directly convert maltodextrin to ~90% yields of Allulose. This is followed by relatively simple purification and crystallization for pure granulated Allulose.

In summary, Bonumose starts with a less processed feedstock (maltodextrin instead of fructose) and still achieves Allulose yields that are 3X-4X higher than fructose-to-Allulose conversions.

Due to Bonumose’s patented enzymatic technology breakthrough, as well as Bonumose’s other technical and business model innovations, Bonumose expects to be able to reduce the cost of Allulose to food & beverage producers globally.

In pursuing its mission to make great-tasting, healthy rare sugars affordable for more people around the world, Bonumose will continue to devote the resources necessary to extend and defend its global intellectual property rights.

Recent News

10/13/2026

ISOThrive Final Phase 2 Results for MHS-1031 Announced at ACG 2026 Demonstrate Statistically Significant and Clinically Meaningful Improvement in Heartburn Frequency and Severity in NERD PPI-Partial Responders

ISOThrive Inc. announced final results from its Phase 2 trial of MHS-1031 in patients with non-erosive reflux disease (NERD) who experience an incomplete response to proton pump inhibitors (PPIs). Peter Swann, MD, Chief Medical Officer of ISOThrive, and David Johnson, MD MACG FASGE VGSF MACP, Professor of Medicine and Chief of Gastroenterology at Eastern Va …

10/13/2026

Virginia Western and Radford University sign 3 new agreements to create seamless transfer for medical laboratory science degree

Virginia Western Community College and Radford University celebrated a strengthened partnership on Monday, Oct. 12, that will enable seamless transfer for students in three health-related programs. Virginia Western President Laura J. Treanor and Radford President Bret Danilowicz signed the articulation agreements in a ceremony on the Virginia Western campus. Virginia Western students who meet all requirements and complete …

10/07/2026

Roanoke Lands $1 Million Federal Grant to Equip RoVa Labs Biotech Incubator

The Roanoke City Council has accepted a $1 million U.S. Small Business Administration grant to purchase advanced laboratory equipment for RoVa Labs, a biotechnology startup incubator that combines biomedical research facilities with business development support. Since opening in May 2026, RoVa Labs has grown to house nine research tenants, and officials say the new funding …